These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
Capricor Therapeutics has recently published the final results from its HOPE-Duchenne clinical trial. This study evaluated the safety and efficacy of a cell therapy called CAP-1002Read more
The 12th UK Neuromuscular Translational Research Conference was held in Newcastle on 4-5 April 2019.
One adult and six children with LGMD2D were treated with the gene therapy MYO-102. The treatment was safely delivered to their muscles and a new clinical trial is being planned.
A new study has found that boys with Duchenne muscular dystrophy on certain steroid regimes have a higher fracture risk than others.
Acclaimed clinical researcher, Professor Laurent Servais, has been appointed Professor of Paediatric Neuromuscular Diseases at the MDUK Oxford Neuromuscular Centre.
The aim of the Mitochondrial Disease Priority Setting Partnership (PSP) is to find the most important unanswered questions about mitochondrial diseases.
Researchers identify a way to improve the efficiency of genome editing technology and boost dystrophin production in a mouse model of Duchenne muscular dystrophy.
Acceleron announced today that the US FDA has granted Orphan Drug designation to their drug ACE-083 for the treatment of patients with Charcot-Marie-Tooth disease (CMT).
This Friday marks the start of British Science Week, a celebration of science, technology, engineering and maths.
Sarepta Therapeutics has announced preliminary results from the MYO-101 trial.
A new study has found that a drug used to treat high blood pressure could be beneficial for the treatment of oculopharyngeal muscular dystrophy (OPMD).